Ionis Pharmaceuticals Q3 2025 Financial Results and Key Updates

Ionis Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, highlighting significant progress in its key programs. The company announced that TRYNGOLZA® generated $32 million in net product sales, marking a nearly 70% increase over the previous quarter. The launch of DAWNZERA™ for hereditary angioedema (HAE) has also shown encouraging results. Additionally, Ionis reported positive Phase 3 results for olezarsen in severe hypertriglyceridemia (sHTG) and zilganersen in Alexander disease, with regulatory submissions planned for late 2025 and early 2026, respectively. The company increased its 2025 financial guidance, reflecting strong revenue performance and a positive outlook for the fourth quarter. Total revenue for the quarter was $157 million, a 17% increase compared to the same period in 2024. Operating expenses rose to $317 million, primarily due to commercialization efforts for TRYNGOLZA, DAWNZERA, and WAINUA. Ionis expects to achieve cash flow breakeven by 2028, driven by growth in product revenues and additional partner revenues.